EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Canbridge Pharmaceuticals Inc (1228) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Canbridge Pharmaceuticals Inc HK$1.55, price HK$2.24, upside -30.7%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · ISIN KYG8587E1061

CP Thin data Sep 27, 2026

Canbridge Pharmaceuticals Inc

1228 · HK

Weak valuationQuality is weak on top of the rich price.

!Fair value HK$1.55 · Overvalued (−30.7%)
!Quality 46/100
!Weak Growth (revenue 5y +33.0 %/yr)
✓Highly profitable · 29.7% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (3/8)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
Watch Canbridge Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$9.30 HK$0.0830 Fair Value HK$1.55 Jan 2012 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.0830 – HK$9.30 · fair‑value band HK$1.09 – HK$2.02 · the HK$2.24 price screens above the HK$1.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Canbridge Pharmaceuticals in your weekly email

Every Wednesday you see whether Canbridge Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.

Show more

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy. The company has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Stock analysis

Canbridge Pharmaceuticals Inc (1228) currently trades at HK$2.24, while our model-based Fair Value estimate is HK$1.55, 30.7% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$1.57 per share, and 0 of the 7 models we run sit above the HK$2.24 price.

Bear case: the Multiples group reads lowest at HK$0.2300, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$1.09 (bear) to HK$2.02 (bull), the price of HK$2.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Canbridge Pharmaceuticals Inc reported revenue of 50.0M CNY in FY2025 versus 31.2M CNY in FY2021, a compound +12.5%/yr. Reported net income was 14.8M CNY in FY2025.

Key figures

Market cap HK$1.0B (≈ $130M) · P/E ratio 70.3 · P/S ratio 20.9 · EPS (TTM) HK$0.1400 · Net margin 29.6% · Return on equity −282% · Return on assets (EBIT) −116% · Operating margin −180%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −31%, 1228 screens richer than that median.

Fair Value models

Bear HK$1.09 Fair Value HK$1.55 Bull HK$2.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.1051 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings HK$0.8600 HK$1.57 HK$2.80 69
Growth-Adj P/E HK$1.09 HK$1.55 HK$2.02 64
P/E Multiple HK$0.5300 HK$0.7100 HK$0.8900 63
All 7 models by family
DCF Models
Owner Earnings HK$0.8600 HK$1.57 HK$2.80 69
Earnings-Based
Graham-Dodd HK$0.2300 HK$1.61 HK$2.26 59
Lynch FV HK$0.8300 HK$1.19 HK$1.54 57
PEG = 1.0 HK$0.8300 HK$1.19 HK$1.54 54
Multiples
P/E Multiple HK$0.5300 HK$0.7100 HK$0.8900 63
P/S Multiple HK$0.1700 HK$0.2300 HK$0.2900 58
Growth Earnings
Growth-Adj P/E HK$1.09 HK$1.55 HK$2.02 64

Open the full fair value analysis →

Notify me when 1228 reaches fair value

Put 1228 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 45 · Market factors (momentum, volatility) 36

Profitability 54
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 50
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 29
Distance to the 52-week high (market factor)
Net Issuance 31
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−41.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Start year 2020 (pandemic)
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,920.7% (2020) → −185.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

1228 screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Canbridge Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Above median
Fair Value upside −30.6% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −40.7% · Bottom 25%
Net margin (TTM) 29.7% · Top 25%
Operating margin (TTM) −180.5% · Bottom 25%
Growth and dividend
Revenue growth −31.2% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 70.3× · Priciest 25%
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 20.43× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Canbridge Pharmaceuticals Inc · Fair Value
HK$1.55 −31%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Canbridge Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/1228

Frequently asked questions

Is Canbridge Pharmaceuticals Inc (1228) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.55 versus a price of HK$2.24, about −31% upside (overvalued).
What is the fair value of 1228?
Our model-based fair value for Canbridge Pharmaceuticals Inc is HK$1.55 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$2.24.
What is the quality score of 1228?
Canbridge Pharmaceuticals Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Canbridge Pharmaceuticals Inc (1228)?
Our model-based price target is the fair value of HK$1.55 (as of Sep 27, 2026) from 7 valuation models. Cautious scenario HK$1.09, optimistic scenario HK$2.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Canbridge Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at HK$1.55, about −31% upside versus a price of HK$2.24 (overvalued). Cautious scenario HK$1.09, optimistic scenario HK$2.02. The calculation is refreshed regularly with new filings.
What is the revenue of Canbridge Pharmaceuticals Inc (1228)?
Canbridge Pharmaceuticals Inc reported trailing-twelve-month revenue of about HK$50.0M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Canbridge Pharmaceuticals Inc (1228)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Canbridge Pharmaceuticals Inc it is HK$1.55 per share (as of Sep 27, 2026), against a price of HK$2.24. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Canbridge Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 1228 trades above its calculated fair value: price HK$2.24, fair value HK$1.55, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1228?
No. The price is what the market pays today (HK$2.24); the fair value is what the company's own numbers justify (HK$1.55). For Canbridge Pharmaceuticals Inc the two are HK$0.6850 per share apart. That gap is exactly why we show both numbers side by side.
How much is Canbridge Pharmaceuticals Inc worth?
The market values Canbridge Pharmaceuticals Inc at about HK$1.0B (market capitalisation, as of Sep 27, 2026). Per share that is HK$2.24; our models calculate a fair value of HK$1.55 per share.
What do the bullish and bearish scenarios say about 1228?
Our models span a range for Canbridge Pharmaceuticals Inc: cautious scenario HK$1.09, base HK$1.55, optimistic HK$2.02 per share (as of Sep 27, 2026, price HK$2.24). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1228?
Canbridge Pharmaceuticals Inc trades at a price-to-earnings ratio of 70.3 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.55 is built from several models across several years. Other multiples: P/S 20.4.
How solid is the balance sheet of Canbridge Pharmaceuticals Inc (1228)?
Balance-sheet figures for Canbridge Pharmaceuticals Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 1228 from its 52-week high?
Canbridge Pharmaceuticals Inc trades at HK$2.24, about 29% below its 52-week high of HK$3.15 and 34% above the low of HK$1.67 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.55 is for.
Which stocks are comparable to Canbridge Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Canbridge Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$2.24, calculated fair value HK$1.55 (−31%), Quality Score 46/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1228 calculated?
We run Canbridge Pharmaceuticals Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Canbridge Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Canbridge Pharmaceuticals Inc (1228)?
The closing price on Sep 30, 2026 was HK$2.24. Our model-based fair value is HK$1.55, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Canbridge Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case (HK$2.02). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.09 to HK$2.02) leaves room in how you read the outcome.

Key figures of Canbridge Pharmaceuticals Inc

How large is the market capitalisation of Canbridge Pharmaceuticals Inc (1228)?
The market capitalisation of Canbridge Pharmaceuticals Inc is HK$1.0B (≈ $130M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Canbridge Pharmaceuticals Inc (1228)?
The price-to-sales ratio of Canbridge Pharmaceuticals Inc is 20.9 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Canbridge Pharmaceuticals Inc (1228)?
Earnings per share at Canbridge Pharmaceuticals Inc are HK$0.1400 (price ÷ EPS = P/E 70.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Canbridge Pharmaceuticals Inc (1228)?
The net margin of Canbridge Pharmaceuticals Inc is 29.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Canbridge Pharmaceuticals Inc (1228)?
The return on equity (ROE) of Canbridge Pharmaceuticals Inc is −282% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Canbridge Pharmaceuticals Inc (1228)?
On an EBIT basis the return on assets of Canbridge Pharmaceuticals Inc is −116% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Canbridge Pharmaceuticals Inc (1228)?
The operating margin of Canbridge Pharmaceuticals Inc is −180% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Canbridge Pharmaceuticals Inc (1228)?
Revenue at Canbridge Pharmaceuticals Inc is growing −31.2% versus a year earlier (3y avg −14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Canbridge Pharmaceuticals Inc (1228) generate?
The free cash flow of Canbridge Pharmaceuticals Inc is −HK$38.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Canbridge Pharmaceuticals Inc (1228) hold?
Canbridge Pharmaceuticals Inc holds more cash than debt, HK$50.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Canbridge Pharmaceuticals Inc in the live analysis

One click puts Canbridge Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.